Navigation Links
ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc.
Date:2/14/2011

udies, including a 255-patient, randomized, double-blind, placebo-controlled phase 3 study in patients with sickle cell disease in acute vaso-occlusive crisis.  The FDA has granted orphan drug designation for poloxamer 188 for the treatment of sickle cell crisis.

About Sickle Cell Disease and Sickle Cell Crisis

Sickle cell disease (SCD) or sickle cell anemia (SCA) is a genetic, autosomal, recessive blood disorder characterized by red blood cells that assume an abnormal, rigid, sickle shape. This sickling is caused by an abnormality in the hemoglobin molecule found in red blood cells which carry oxygen throughout the body. Sickled red blood cells cannot pass through capillaries and may occlude capillaries and small blood vessels. This blockage can cause a wide range of serious and life-threatening conditions, including chronic hemolytic anemia, chronic pain and acute painful crisis, stroke, acute chest syndrome, as well as cumulative damage to tissues and organs.

Patients with SCD experience an average life expectancy of approximately 40 years. According to the National Institutes of Health (NIH) and the Sickle Cell Disease Association of America (SCDAA), it is estimated that over 70,000 people have sickle cell disease and about 1,000 babies are born with the disease each year in the United States.

Vaso-occlusive crisis is caused by sickle-shaped red blood cells that obstruct capillaries and restrict blood flow to an organ, resulting in ischemia (restriction of blood supply), pain, necrosis, and often organ damage. The frequency, severity, and duration of these crises can vary considerably.

Conference Call Information

ADVENTRX will hold a conference call today at 8:30 am ET to discuss the potential acquisition. Interested parties may access the conference call by dialing (800) 860-2442 from the U.S. and (412) 858-4600 from outside the U.S. and requesting the ADVENTRX Pharmaceuticals Corporat
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ADVENTRX to Provide Update Regarding Pipeline Expansion Efforts
2. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIOCEO & Investor Conference on February 15
3. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
4. ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing
5. ADVENTRX Pharmaceuticals Announces Capital Raise of $22.5 Million
6. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
7. ADVENTRX Pharmaceuticals to Present at the 4TH Annual OneMedForum Business Development and Investment Conference on January 11
8. ADVENTRX Requests Meeting with FDA to Discuss ANX-514 Study
9. ADVENTRX Reports Third Quarter Financial Results
10. ADVENTRX to Present at the Wall Street Analyst Forum 21st Annual Institutional Investor Conference on November 11
11. ADVENTRX Submits Exelbine™ New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Today, DripDrop, the ... the formation of the DripDrop Foundation, with its ... dehydration worldwide. Utilizing scientific advancements in Oral Rehydration ... to reduce dehydration and healthcare costs through strategic ... "DripDrop has been used in ...
(Date:9/23/2014)... , Sept. 23, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... new additions to its Scientific Advisory Board.  The new ... Anthony Davies , PhD. Dr. Acker is ...
(Date:9/22/2014)... BARCELONA , España, September 23, 2014 ... nube permite que los patrocinadores de ensayos clínicos satisfagan ... a la accesibilidad y exhaustividad de los expedientes permanentes ... La mayor encuesta sobre TMF en el ... un aumento en el número de patrocinadores de ensayos ...
Breaking Medicine Technology:DripDrop Forms Foundation To Scale Relief Efforts 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 2El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 3El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 4El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 5
... Adeona Pharmaceuticals, Inc. (AMEX: ... for serious central nervous system diseases, announced today ... the randomized, double-blind, placebo-controlled, multi-center clinical trial of ... multiple sclerosis (MS) in women, per the original ...
... MARLBOROUGH, Mass., Sept. 19, 2011 Advanced Cell Technology, ... of regenerative medicine, announced today that it has been ... the Company,s proprietary method for generating and expanding hemangioblast ... an exclusive license to commercialize the patented technology in ...
Cached Medicine Technology:Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 2Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 3Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 4Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 5ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 2ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 3ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 4
(Date:9/23/2014)... Westlake Village, CA (PRWEB) September 23, 2014 ... Sedation Dental Office is now offering complimentary oral sedation ... about 15 percent of Americans suffer from dental anxiety ... merely uncomfortable for patients; they can also keep patients ... dental anxiety or phobia in Westlake Village and surrounding ...
(Date:9/23/2014)... September 23, 2014 PM360, a leading ... the pharmaceutical industry with their annual Trailblazer Awards on ... gala banquet at Gotham Hall in New York City, ... representing top talent and brands. , ... says Anna Stashower, CEO and Publisher of PM360. “We ...
(Date:9/23/2014)... 23, 2014 Kenall Manufacturing, a ... its MedMaster™ M4 product line with a new ... M4 product line – currently available with 2'×2' ... providing more flexibility when designing lighting for the ... M4 Series include:, •Three sizes available to ...
(Date:9/23/2014)... Rockville, MD (PRWEB) September 23, 2014 ... a proposal by the World Health Organization (WHO) regarding ... , USP supports the effort by the Expert Group ... develop a consensus-based global approach to the naming of ... principles critical to the quality assessment of these drugs. ...
(Date:9/23/2014)... 2014 Catalent Pharma Solutions, ... technologies and development solutions for drugs, biologics ... it had reached an exclusive development and ... Cingulate Therapeutics (CTx), to support the development ... products for the treatment of Attention Deficit/Hyperactivity ...
Breaking Medicine News(10 mins):Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 2Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 4Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 5Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 6Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3Health News:USP Comments to WHO Regarding Biologics Qualifier Proposal 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 3
... HOUSTON - A $4 million, five-year grant from the ... Networks Program Center (CNPC), called Latinos Contra El Cancer, ... The center is a joint project of The ... School of Public Health and The University of Texas ...
... low-dose radiation from cardiac imaging and other procedures after ... of cancer, found a new study published in ... link only) http://www.cmaj.ca/embargo/cmaj100463.pdf . The use of ... (CT) angiography and nuclear scans, is increasing which has ...
... of Sweden decided to introduce a special blessing for ... making a distinction between genuine homosexuality and promiscuous homosexuality, ... a new thesis in religious studies at the University ... between opponents and supporters of the decision. "It ...
... rates continue to rise, University of Missouri researchers are ... an effective and inexpensive way for people with addictive ... Matthew Martens, associate professor of Educational, School and Counseling ... team of researchers received a $172,500 grant from ...
... produced by the DNA of tumor cells, researchers have ... new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists ... of a drug that blocks the protein,s activity. ... target for high-risk neuroblastoma," said pediatric oncologist Kristina A. ...
... two new works, an anthropologist tackles a perplexing question relating ... tolerate and even celebrate the public display of ... of Real Human Bodies " is the most widely attended ... professor of anthropology at the University of Illinois and author ...
Cached Medicine News:Health News:Project connects researchers, Latino communities to prevent cancer 2Health News:Project connects researchers, Latino communities to prevent cancer 3Health News:Risk of cancer increases with exposure to low-dose radiation 2Health News:Supporters and opponents of a special blessing for homosexuals share many values 2Health News:Simple feedback could be effective therapy for addictive behaviors 2Health News:Protein may be key to new treatment in a childhood cancer 2Health News:Protein may be key to new treatment in a childhood cancer 3Health News:Anthropologist: 'Body Worlds' visitors confront bodies but not death 2Health News:Anthropologist: 'Body Worlds' visitors confront bodies but not death 3
QualCraft™ Radiation Protection Eyewear providex maximum comfort and eye protection! Lenses made of 0.75 mm leaded glass. Side shields of 0.30 mm leaded acrylic help seal out scatter radiation ...
Clip-On Glasses clip onto regular eyewear frames. Plano (nonprescription) only. Will not fit over high-plus or high-minus presciptions, or over glasses with thick frames. Black wire frames. Wt. 63 g....
Qualcraft™ Radiation Readers, Wraparound Glasses. Protect yourself and have close-vision clarity....
The Bronze Metalite Constructed of optical-grade steel with bronze electroplate. Fitted lead side shields that create a seal to the front of the lenses for increased scatter protection....
Medicine Products: